Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3047% below fair value
$1.32−0.04 (-2.94%)
Close on Nov 16, 2026Market cap $6.07MP/E –Yield –
Biomerica ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Biomerica's ebitda for the twelve months ending Aug 31, 2026 was -$5.36M. For fiscal 2026 it was -$5.24M. The highest annual figure on record is $701.33K in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$5.24M | – |
| FY2025 | May 31, 2025 | -$5.05M | – |
| FY2024 | May 31, 2024 | -$6.29M | – |
| FY2023 | May 31, 2023 | -$7.14M | – |
| FY2022 | May 31, 2022 | -$4.20M | – |
| FY2021 | May 31, 2021 | -$7.39M | – |
| FY2020 | May 31, 2020 | -$2.64M | – |
| FY2019 | May 31, 2019 | -$2.31M | – |
| FY2018 | May 31, 2018 | -$1.37M | – |
| FY2017 | May 31, 2017 | -$809.75K | – |
| FY2016 | May 31, 2016 | -$670.67K | – |
| FY2015 | May 31, 2015 | -$492.38K | – |
| FY2014 | May 31, 2014 | -$269.08K | -138.4% |
| FY2013 | May 31, 2013 | $701.33K | +7.5% |
| FY2012 | May 31, 2012 | $652.30K | – |
| FY2011 | May 31, 2011 | -$2.22K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$1.21M | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$1.52M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$1.28M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$1.35M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$1.10M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$1.54M | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$1.19M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$971.00K | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$1.35M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$1.51M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$1.98M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$1.59M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$1.21M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$1.82M | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.64M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$1.65M | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$2.04M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$1.50M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$81.50K | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$1.10M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$1.51M | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.70M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$2.14M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.69M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.87M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$798.32K | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$891.06K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$465.42K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$480.06K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$741.72K | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$684.81K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$457.55K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$427.49K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$620.57K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$294.50K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$260.83K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$194.81K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$314.72K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$284.03K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$182.04K | – |
See a number that looks wrong?